Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Verici Dx Plc ( (GB:VRCI) ) has shared an update.
Verici Dx has reported significant commercial progress in the first half of 2025, with the first revenues from their lead product, Tutivia™, a test for acute rejection post-transplant. The company has raised £6.35m to support revenue scale-up, extending their cash runway into H2 2026. Tutivia™ has attained Medicare coverage, facilitating increased adoption across US transplant centers. The company is poised for growth with expanded commercial operations and expects significant acceleration in testing volumes in H2 2025 and beyond.
The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.
Spark’s Take on GB:VRCI Stock
According to Spark, TipRanks’ AI Analyst, GB:VRCI is a Neutral.
The overall score is primarily influenced by financial performance challenges, including ongoing losses and cash flow issues. Technical analysis provides a neutral outlook, while valuation metrics are weak due to negative earnings.
To see Spark’s full report on GB:VRCI stock, click here.
More about Verici Dx Plc
Verici Dx plc is a developer of advanced clinical diagnostics focused on organ transplant, particularly kidney transplants. The company offers a suite of tests that utilize RNA sequencing technology to assess the risk of rejection and improve patient outcomes. Their products include Tutivia™, a test for acute rejection post-transplant, and Pre-Transplant Risk Assessment test (PTRA), licensed to Thermo Fisher.
Average Trading Volume: 2,147,502
Technical Sentiment Signal: Sell
Current Market Cap: £9.46M
See more data about VRCI stock on TipRanks’ Stock Analysis page.